低钠透析液对居家及自助卫星中心血透患者左心室质量的影响:随机临床试验
这项随机试验将99例居家或自助卫星中心血透患者分为低钠透析液组(135 mM)和常规透析液组(140 mM),干预12个月。结果显示低钠透析液虽显著降低透析间期体重增长、细胞外液量和血浆BNP,但未改变左心室质量指数,且增加透析中低血压风险。
要点
- 低钠透析液(135 mM)未降低左心室质量指数
- 低钠透析液改善液体状态但增加透析中低血压
- 透析中低血压致5例干预组患者未能完成试验
核心结论
- 与常规透析液(140 mM)相比,低钠透析液(135 mmol/L)未降低左心室质量指数,尽管改善了液体状态。
研究设计与样本
- 随机临床试验,纳入99例年龄>18岁、透析前血清钠≥135 mM、在居家或自助卫星中心接受血透的患者。
- 干预组使用低钠透析液(135 mM),对照组使用常规透析液(140 mM),疗程12个月。
- 排除透析频率>3.5次/周、使用钠 profiling 或血液透析滤过的患者。
- 主要结局为心脏磁共振成像测定的左心室质量指数。
主要发现
- 99例参与者中位年龄51岁,67例男性,31例糖尿病,59例左心室肥厚。
- 12个月随访期间,低钠透析液组左心室质量指数较对照组无变化。
- 低钠透析液组在6和12个月时透析间期体重增长、细胞外液量和血浆B型利钠肽浓度显著降低(干预组与对照组比值)。
- 低钠透析液组透析中低血压风险增加:6个月OR 7.5(95%CI 1.1–49.8),12个月OR 3.6(95%CI 0.5–28.8)。
- 干预组5例因低血压未能完成试验;健康相关生活质量、口渴或口干、膳食钠摄入无显著影响。
临床怎么用
- 对于居家或自助卫星中心血透患者,采用低钠透析液(135 mM)以降低左心室质量为目的缺乏证据支持。
- 使用低钠透析液时需警惕透析中低血压风险增加,尤其6个月内风险显著升高。
局限性
- 样本量较小(99例),可能影响统计效能。
- 排除透析频率>3.5次/周及使用钠profiling或血液透析滤过的患者,结果外推受限。
- 12个月透析中低血压的OR值置信区间宽且跨越1,需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Fluid overload in patients undergoing hemodialysis contributes to cardiovascular morbidity and mortality. There is a global trend to lower dialysate sodium with the goal of reducing fluid overload. METHODS: To investigate whether lower dialysate sodium during hemodialysis reduces left ventricular mass, we conducted a randomized trial in which patients received either low-sodium dialysate (135 mM) or conventional dialysate (140 mM) for 12 months. We included participants who were aged >18 years old, had a predialysis serum sodium ≥135 mM, and were receiving hemodialysis at home or a self-care satellite facility. Exclusion criteria included hemodialysis frequency >3.5 times per week and use of sodium profiling or hemodiafiltration. The main outcome was left ventricular mass index by cardiac magnetic resonance imaging. RESULTS: The 99 participants had a median age of 51 years old; 67 were men, 31 had diabetes mellitus, and 59 had left ventricular hypertrophy. Over 12 months of follow-up, relative to control, a dialysate sodium concentration of 135 mmol/L did not change the left ventricular mass index, despite significant reductions at 6 and 12 months in interdialytic weight gain, in extracellular fluid volume, and in plasma B-type natriuretic peptide concentration (ratio of intervention to control). The intervention increased intradialytic hypotension (odds ratio [OR], 7.5; 95% confidence interval [95% CI], 1.1 to 49.8 at 6 months and OR, 3.6; 95% CI, 0.5 to 28.8 at 12 months). Five participants in the intervention arm could not complete the trial because of hypotension. We found no effect on health-related quality of life measures, perceived thirst or xerostomia, or dietary sodium intake. CONCLUSIONS: Dialysate sodium of 135 mmol/L did not reduce left ventricular mass relative to control, despite improving fluid status. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: The Australian New Zealand Clinical Trials Registry, ACTRN12611000975998.
引用
- Marshall MR, Vandal AC, de Zoysa JR, et al. Effect of Low-Sodium versus Conventional Sodium Dialysate on Left Ventricular Mass in Home and Self-Care Satellite Facility Hemodialysis Patients: A Randomized Clinical Trial. J Am Soc Nephrol. 2020. PMID: 32188697. doi:10.1681/ASN.2019090877
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。